Najlepsi lekarze wykonujący terapię biologiczną w Ramacie Ganie – TOP 4 lekarzy

Dr. Amos Toren is a pediatric hemato-oncologist at Sheba Medical Center. He served as Director of the Pediatric Hemato-Oncology and Bone Marrow Transplant Division. Dr. Toren holds a PhD in Human Genetics. He specializes in CAR T-cell therapy and bone marrow transplantation for children. Forbes Israel has recognized his expertise in hematology.

• Served as the Head of the Hematology Division at Tel Aviv University.
• Treats complex cases of leukemia, lymphoma, and rare pediatric cancers.
• Member of the American Society of Hematology and European Group for Blood and Marrow Transplantation.
• Collaborates on research with the NIH and St. Jude Children’s Research Hospital.

Dr. Hana Golan heads the Pediatric Hemato-Oncology and Bone Marrow Transplantation Division at Sheba Medical Center. She specializes in high-risk pediatric tumors and complex childhood cancers. Dr. Golan serves as the principal investigator for the High-Risk Neuroblastoma ESIOP protocol. She practices at a hospital ranked among the global top 10 by Newsweek.

• National coordinator of multicenter oncology protocols and international Phase I/II clinical trials.
• Performs bone marrow transplants and CAR T-cell therapy for pediatric patients.
• Expert in neuroblastoma, leukemia, and treatment-resistant malignancies.
• Senior Lecturer at the Sackler Faculty of Medicine at Tel Aviv University.

Dr. Amit Tirosh is the Head of the Neuroendocrine Tumors (NET) Service at Sheba Medical Center. He is an international authority on von Hippel–Lindau (VHL) disease and hereditary tumor syndromes. Dr. Tirosh contributed to global clinical guidelines for VHL management. He also leads the Endocrine Oncology Bioinformatics Lab at Sheba.

• Contributor to the international expert panel on VHL management guidelines.
• Authored over 40 peer-reviewed papers in journals like JAMA and Gastroentrology.
• Maintains research affiliations with the NIH and the Weizmann Institute.
• Performs specialized NET treatments, including Lutetium-177 therapy and PRRT.